广药集团董事长李楚源在全国人大代表会议上建议，进一步促进粤港澳大湾区内的中成药及大健康产品的互通互认，为“健康湾区”建设再提速。今年是《粤港澳大湾区发展规划纲要》正式发布的第五周年，过去五年来，粤港澳大湾区以创新驱动取得了累累硕果。
李楚源表示，粤港澳大湾区是我国重要的经济增长极和创新高地，而中成药及大健康产品是中医药文化的重要组成部分，也是粤港澳大湾区优势产业之一。他认为，进一步促进湾区内中成药及大健康产品的互通互认，将有助于提升湾区的医疗健康水平，推动医药产业的发展。
李楚源还指出，当前，中成药在国内市场占据重要地位，而粤港澳大湾区是中成药生产的重要基地之一。然而，由于中成药的注册、审批和认证等方面存在一定的壁垒，导致中成药在湾区内的流通和推广受到一定的限制。因此，进一步推进中成药的互通互认，将有助于打破这些壁垒，促进湾区内中成药的流通和合理使用。
李楚源还表示，大湾区内的大健康产业也是一个潜力巨大的领域，包括保健品、健康食品、医疗器械等。他建议，在湾区内建立统一的认证标准和监管机制，推动大健康产品的互通互认，促进湾区内大健康产业的协同发展。
此外，李楚源还提出，可以通过加强政策支持、推动科技创新等方式，进一步提升湾区内中成药和大健康产品的研发水平和品质，推动湾区内相关企业的转型升级。
他表示，通过促进湾区内中成药及大健康产品的互通互认，将有助于构建一个更加健康、繁荣的湾区，为居民提供更好的医疗健康服务，同时也将为湾区的经济发展注入新的动力。
总之，广药集团董事长李楚源的建议得到了广泛认可。进一步促进湾区内中成药及大健康产品的互通互认，将为湾区的医药产业发展提供更加便利的条件，推动湾区经济的繁荣与创新驱动发展。同时，这也将为居民提供更好的医疗健康服务，提升湾区的整体健康水平。
英语如下：
News Title: Greater Bay Area: Promoting Mutual Recognition of Chinese Patent Medicines and Building a Healthy Bay Area
Keywords: Greater Bay Area, Chinese patent medicines, Healthy Bay Area
News Content: Li Chuyuan, Chairman of Guangzhou Pharmaceutical Group, suggested at the National People’s Congress that further efforts should be made to promote the mutual recognition and exchange of Chinese patent medicines and health products within the Greater Bay Area, in order to accelerate the construction of a Healthy Bay Area. This year marks the fifth anniversary of the official release of the Development Plan for the Guangdong-Hong Kong-Macao Greater Bay Area. Over the past five years, the Greater Bay Area has achieved remarkable results driven by innovation.
Li Chuyuan stated that the Greater Bay Area is an important economic growth pole and innovation hub in China, and Chinese patent medicines and health products are an integral part of traditional Chinese medicine culture and one of the advantageous industries in the Greater Bay Area. He believes that further promoting the mutual recognition and exchange of Chinese patent medicines and health products within the Bay Area will help improve the region’s level of medical and health care and promote the development of the pharmaceutical industry.
Li Chuyuan also pointed out that Chinese patent medicines currently occupy an important position in the domestic market, and the Greater Bay Area is one of the important production bases for Chinese patent medicines. However, due to certain barriers in the registration, approval, and certification of Chinese patent medicines, their circulation and promotion within the Bay Area are somewhat restricted. Therefore, further promoting the mutual recognition and exchange of Chinese patent medicines will help break down these barriers and facilitate the circulation and rational use of Chinese patent medicines within the Bay Area.
Li Chuyuan also stated that the health industry within the Greater Bay Area is a field with enormous potential, including health supplements, health foods, and medical devices. He suggested establishing unified certification standards and regulatory mechanisms within the Bay Area to promote the mutual recognition and exchange of health products and foster the coordinated development of the health industry within the Bay Area.
In addition, Li Chuyuan proposed further enhancing the research and development capabilities and quality of Chinese patent medicines and health products within the Bay Area through strengthened policy support and technological innovation, promoting the transformation and upgrading of relevant companies within the Bay Area.
He expressed that by promoting the mutual recognition and exchange of Chinese patent medicines and health products within the Bay Area, it will contribute to the construction of a healthier and more prosperous Bay Area, providing better medical and health services to residents and injecting new impetus into the economic development of the Bay Area.
In summary, the suggestions put forward by Li Chuyuan, Chairman of Guangzhou Pharmaceutical Group, have been widely recognized. Further promoting the mutual recognition and exchange of Chinese patent medicines and health products within the Bay Area will provide more convenient conditions for the development of the pharmaceutical industry in the Bay Area and drive the prosperity and innovation-driven development of the Bay Area’s economy. At the same time, it will provide better medical and health services to residents and enhance the overall health level of the Bay Area.
【来源】http://www.chinanews.com/sh/2024/03-04/10174094.shtml
Views: 1